北京锦篮基因科技有限公司
新闻资讯
新闻资讯
关注锦篮的点滴进展
锦篮基因AAV病毒载体基因治疗药物中国临床试验进展即将亮相国际舞台

2024-04-30

分享:

The Global Cell & Gene Therapy Summit 2024(CGT Summit 2024)将于当地时间2024年7月8-10日在美国波士顿马萨诸塞州举办。北京锦篮基因科技有限公司(以下简称“锦篮基因”)将分享锦篮自主研发的基因治疗药物GC101治疗脊髓性肌萎缩症、GC301治疗庞贝病的中国临床试验进展。本次分享是锦篮基因注册临床试验进展在国际舞台的首次主动公开,值此契机将促进锦篮基因与国内外基因治疗领域专家学者的交流,加速将科学发现转化为临床应用,为更好、更早的造福全球人类健康奠定基础。



Time:July 08-10, 2024 

Venue:Boston, MA, USA

Sessions:Gene Therapy: Methods, Strtegies & Clinical Applications

Poster Presentation Title

Spinal Muscular Atrophy and Pompe Disease Gene Therapy Clinical Trials in China

Presenting Author Xiaodong Wang, Ph.D

Trained in human genetics and serving as the vice president of medical affairs at GeneCradle Therapeutics, Dr. Wang is actively involved in clinical trial protocol designs, data analysis, and results discussion with investigators.

Abstract

Spinal muscular atrophy (SMA) and Pompe disease (PD) are both rare diseases that can be life-threatening or significantly impact the quality of life. GC101 and GC301 are AAV-based gene therapy drugs specifically designed to treat SMA and PD, respectively. Intrathecal administration of GC101 and intravenous administration of GC301 have demonstrated safety and provided clinically significant improvement in  survival, motor function, and achievement of motor milestones, which were not previously expected in  patients with SMA and PD.


ABOUT SUMMIT

Cell and gene therapy represent intersecting fields of biomedical research with the shared goal of treating, preventing, or curing diseases. These approaches are aimed at understanding the underlying causes of various diseases, ranging from rare and complex conditions to those with genetic or acquired origins. This rapidly expanding treatment approach is poised to address significant unmet medical needs across a wide range of conditions. However, the conceptual framework of cell and gene therapy is both expensive and requires precision, presenting challenges for industrial implementation and patient accessibility.

Emerging tools and techniques in the market have facilitated the adaptability and utilization of cell and gene therapy. These advancements have made it easier to employ CGT as a method of treating diseases, including rare and complex disorders, single gene disorders, and various types of cancer. With these advancements in mind, the International Summit on Cell and Gene Therapy serves as a platform to explore the fundamental concepts of these transformative therapies. The summit brings together experts from academia and industry to discuss a range of topics related to cell and gene therapy, including ethical considerations, social implications, tools, techniques, marketing strategies, and the commercialization of cell and gene therapy products. It also showcases the latest research progress in CGT and explores opportunities for further enhancements in availability and productivity of these therapies. By fostering collaboration and knowledge exchange, the summit aims to advance the field of cell and gene therapy, benefiting patients worldwide.

关于锦篮基因

北京锦篮基因科技有限公司是一家以AAV载体递送技术介导的基因治疗药物开发为核心业务的国家高新技术企业,以推动中国罕见病基因药物从基础走向临床和市场为使命,造福患者及家庭。公司专注于遗传性神经肌肉疾病、遗传代谢疾病、溶酶体疾病以及眼科疾病等领域基因治疗药物开发,并通过推进罕见病基因药物研发和临床应用,更深入认识生命健康,将基因治疗技术及产品从罕见病过渡到慢性病和其它重大疾病的治疗和康复。